At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Ramipril +3 moredrug
Likely dose
Ramipril 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi
In Brief
A clinical study evaluating Ramipril, Tadalafil, and 1 other intervention for Metabolic Syndrome. Completed, enrolled 27 participants.
Detailed Summary
This study will measure the effect of the agent tadalafil on glucose and insulin homeostasis in people with metabolic syndrome in the presence and absence of an ACE inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
Countries--
CollaboratorsNational Institutes of Health (NIH)
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedSep 2008
Primary CompletionJan 2009
Study CompletionMay 2009
TodayJul 2026
First PostedSep 10, 2008
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.8 years ago
Interventions
Ramiprildrug
Ramipril 10 mg per day for three weeks
Tadalafildrug
tadalafil 10 mg every other day for three weeks
placebodrug
placebo matching ramipril
placebodrug
placebo matching tadalafil